News

Iovance Sued Over Treatment Claims Before Worst Selloff in Years
Iovance Biotherapeutics Inc. misled investors about factors affecting revenue for two cancer therapies in advance of a recent financial report that caused a 45% stock drop, investors say in a pair of ...
Baylor College of Medicine4d
Capsida receives FDA IND Clearance for its first-in-class, IV-administered gene therapy for STXBP1-developmental and epileptic encephalopathy
Researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children’s ...